Advertisement

Search Results

Advertisement



Your search for The ASCO Post Staff ,The ASCO Post Staff matches 6181 pages

Showing 3001 - 3050


sarcoma
immunotherapy

Emily Z. Keung, MD, on Interactions of Sarcoma, Immune Infiltrates, and Checkpoint Blockade

Emily Z. Keung, MD, of The University of Texas MD Anderson Cancer Center, discusses the complex interactions of immune infiltrates and neoadjuvant immune checkpoint blockade (ICB) in patients with resectable soft-tissue sarcoma. These interactions may hold the key to understanding pathologic...

solid tumors
immunotherapy

Kim A. Reiss, MD, on HER2-Overexpressing Solid Tumors: First-in-Human Study of Anti-HER2 CAR Macrophages

Kim A. Reiss, MD, of the University of Pennsylvania, discusses results of a phase I trial of a CAR-M engineered macrophage cancer therapy, known as CT-0508, for patients with solid tumors that overexpress HER2. CAR-M, designed to exploit the natural role of macrophages to initiate an antitumor...

prostate cancer

Does Yoga Improve Quality of Life in Men With Prostate Cancer?

A diagnosis of prostate cancer may translate to approximately a 30% increase in the incidence of depression and anxiety, a fourfold higher risk of heart attack, and a twofold higher risk of suicide. A study published by Kaushik et al in Prostate Cancer and Prostatic Diseases aimed to evaluate the...

gynecologic cancers

FDA Approves Pafolacianine to Help Identify Ovarian Cancer Lesions

On November 29, the U.S. Food and Drug Administration (FDA) approved pafolacianine (Cytalux), a targeted fluorescent imaging agent intended to assist surgeons in identifying ovarian cancer lesions. The drug, which is indicated for use in adult patients with ovarian cancer and is administered in the ...

lung cancer
immunotherapy

Stephanie T. Schmidt, PhD, on NSCLC: The Immunomodulatory Impact of Neoadjuvant Chemotherapy and Immune-Based Treatments

Stephanie T. Schmidt, PhD, of The University of Texas MD Anderson Cancer Center, discusses the first integrated examination of the immunomodulatory effects of neoadjuvant chemotherapy, nivolumab, and nivolumab plus chemotherapy in resected non–small cell lung cancer (Abstract 962).

skin cancer

Research Assesses Molecular Hallmarks of Moles and Melanomas

Moles and melanomas both originate from the same type of cell—melanocytes. A study published by McNeal et al in eLife Magazine aimed to explain how common moles and melanomas form and why moles can subsequently change into melanoma. Melanocytes are cells that give color to the skin to protect it...

FDA Approves Maribavir for Posttransplant CMV

On November 23, the U.S. Food and Drug Administration (FDA) approved the antiviral maribavir (Livtencity) for adult and pediatric patients aged 12 years and older (and weighing at least 35 kg) with posttransplant cytomegalovirus (CMV) infection or disease that is not responsive (with or without...

SARC Appoints Jonathan Fletcher, MD, to New Role of Chief Scientific Officer

Sarcoma Alliance for Research Through Collaboration (SARC) recently announced the appointment of Jonathan ­Fletcher, MD, as Chief Scientific Officer (CSO). This is a new role at the nonprofit cancer research organization, a leader in collaborative discovery, translational research, and clinical...

New Breast Cancer Survivorship Program Launched by USC Norris Comprehensive Cancer Center

There are currently more than 3.8 million breast cancer survivors living in the United States, and 3 out of 10 women with invasive breast cancer will develop metastases. However, if some breast cancer cells remain after treatment, the amount is often too small to be detected by mammograms or...

Eric P. Winer, MD, FASCO, to Lead Yale Cancer Center and Smilow Cancer Hospital

After an extensive national search, Yale School of Medicine and Yale New Haven Health have announced that Eric P. Winer, MD, FASCO, will be the next Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale New Haven, effective February 1, 2022. Nita Ahuja, MD, MBA,...

American Cancer Society and Flatiron Health Announce Recipients of Real-World Data Impact Award

The American Cancer Society (ACS) and Flatiron Health recently presented the 2021 Real-World Data Impact Awards, which will support research into health disparities among patients with advanced pancreatic and breast cancers. This year marks the third year of the joint grant-making program, under...

Northwell Names Fidel Valea, MD, to Leadership Roles in Gynecologic Oncology

Fidel Valea, MD, recently announced his appointment as System Chief of Gynecologic Oncology at Northwell Health and Director of Gynecologic Oncology at the Northwell Health Cancer Institute. He will see patients in New Hyde Park, New York, and Manhattan. In his role as System Chief of Gynecologic...

Craig Sauter, MD, Joins Cleveland Clinic

Jame Abraham, MD, FACP, Chairman of the Department of Hematology and Medical Oncology at the Taussig Cancer Institute, Cleveland Clinic Lerner College of Medicine, recently announced the appointment of Craig Sauter, MD, as the new Director of Blood and Marrow Transplant Program at the Cleveland...

MSK Appoints Saad Z. Usmani, MD, MBA, FACP, Chief of Myeloma Service

Physician leader and clinical and translational investigator Saad Z. Usmani, MD, MBA, FACP, recently joined Memorial Sloan Kettering Cancer Center (MSK) as Chief of Myeloma Service. He was also appointed Professor at the Joan & Sanford I. Weill Medical College of Cornell University. Dr....

Purdue Center for Cancer Research Receives $1.5 Million for Endowed Professorship

The Henry E. Haller Jr. Foundation and the Walther Cancer Foundation together will donate a total of $1.5 million to the Purdue Center for Cancer Research and the College of Science in Cancer Biology in West Layfayette, Indiana. A donation of $750,000 from the Henry E. Haller Jr. Foundation was...

MD Anderson and the Rare Cancer Research Foundation Announce Collaboration

The University of Texas MD Anderson Cancer Center and the Rare Cancer Research Foundation have launched a collaboration designed to accelerate the development of new treatments for rare cancers by empowering all patients in the United States to contribute tumor samples directly to MD Anderson for...

FDA Pipeline: Reviews and Designations in Hematology

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to a gene therapy for patients with β-thalassemia, and Fast Track designation to a SETD2 inhibitor for patients with relapsed or refractory diffuse large B-cell lymphoma. Priority Review: Betibeglogene Autotemcel for...

solid tumors

FDA Approves Sirolimus Protein-Bound Particles for Rare Sarcoma

On November 22, the U.S. Food and Drug Administration (FDA) approved sirolimus protein-bound particles for injectable suspension (albumin-bound; Fyarro) for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).  AMPECT Trial Efficacy ...

issues in oncology

Study Finds Unique Genomic and Molecular Features in Young Adult Patients With Cancer

Young adults diagnosed with cancer may require different treatments than those received by older patients, according to a study that systematically compared the genomes of 14 different types of cancers affecting both younger and older adults. The results, published by Lee et al in Cell Reports,...

sarcoma

From Cancer Survivor to Citizen Astronaut

When I was diagnosed with osteosarcoma of my left femur nearly 20 years ago, I remember telling my parents that I didn’t want to die. The diagnosis was terrifying because all the people I knew who had cancer had passed away, and I thought this cancer would kill me, too. That evening, my dad went...

breast cancer

Exercise Program May Help to Reduce Upper Limb Disability After Breast Cancer Surgery

Arm and shoulder disability and pain that some women who have had breast cancer surgery experience as a side effect of their procedure may be reduced by following a physiotherapy-led exercise program, according to a new study published by Bruce et al in The BMJ. The report showed an improvement in...

breast cancer

Yongbae Kim, MD, on Elective Internal Mammary Node Irradiation in Women With Node-Positive Breast Cancer: Results of a Randomized Phase III Trial

Yongbae Kim, MD, of the Yonsei Cancer Center and Yonsei University College of Medicine, discusses findings that showed the use of internal mammary area irradiation (IMNI) in regional nodal irradiation did not significantly improve disease-free survival for women with node-positive breast cancer....

hematologic malignancies

Ronald S. Go, MD, on Managing Histiocytic Neoplasms: New NCCN Guidelines

Ronald S. Go, MD, of Mayo Clinic Cancer Center, discusses the new NCCN Clinical Practice Guidelines in Oncology for the most common types of histiocytic neoplasms in adults—Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease, all considered rare among hematologic...

lung cancer

2021 State of Lung Cancer Report Finds Survival Has Increased but Remains Significantly Lower for People of Color

The new 2021 State of Lung Cancer report reveals that the 5-year survival rate for lung cancer increased from 14.5% nationally to 23.7%, yet it remains significantly lower among communities of color. The American Lung Association’s fourth annual report also highlights how the toll of lung cancer...

multiple myeloma

Model May Help Identify Subtypes of Multiple Myeloma

Researchers have developed a new model that uses DNA and RNA sequencing data from hundreds of patients to identify specific genes and genetic alterations responsible for subtypes of multiple myeloma. They also identified potential targeted treatments based on the findings, which were reported by...

covid-19

FDA Expands Eligibility for COVID-19 Vaccine Boosters

On November 19, the U.S. Food and Drug Administration (FDA) amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals aged 18 years and older after completion of primary vaccination with any ...

multiple myeloma

Shaji K. Kumar, MD, on Newly Diagnosed Multiple Myeloma: How Many Drugs Are Enough?

Shaji K. Kumar, MD, of the Mayo Clinic Cancer Center, discusses the evolving treatment paradigm for patients with newly diagnosed multiple myeloma in which clinical trials are suggesting the addition of a fourth drug to induction treatment regimens and new drug classes are improving treatment for...

leukemia

Study Examines Availability of All-Trans Retinoic Acid in U.S. Hospitals

New research published by Geer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that fewer than one-third of hospitals in the United States had immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. ATRA is initiated early in the...

kidney cancer
immunotherapy

FDA Approves Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma

On November 17, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of disease recurrence following nephrectomy or nephrectomy and resection of metastatic lesions....

genomics/genetics
issues in oncology

Study Reveals Genomic Differences Between 14 Tumor Types in Younger vs Older Adults

The results of a study published by Lee et al in Cell Reports suggest that several genetic hallmarks may play key roles in identifying precise treatment options for young adult patients with cancer. The investigators, who systematically compared the genomes of 14 different types of cancers that...

lung cancer
covid-19

French Study Finds COVID-19 Vaccine Effective in Patients With Lung Cancer

In a new study published by Gounant et al in the Journal of Thoracic Oncology, researchers from France showed that SARS–CoV-2 vaccines are safe and effective in patients with thoracic cancer, most of whom are immunized after two doses. A third shot given to 11% of patients with persistent low...

immunotherapy

Study Explores Method to Selectively Grow Tumor-Targeting T Cells for Cancer Therapy

A preclinical study published by Arnaud et al in Nature Biotechnology has demonstrated the utility and efficacy of a highly efficient method to generate large numbers of immune cells specifically engineered to recognize neoantigens and destroy the tumors that express them. Developed by a team of...

hematologic malignancies

FDA Approves Ropeginterferon alfa-2b-njft for Adults With Polycythemia Vera

The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with polycythemia vera. The new agent is a monopegylated, long-acting interferon, which exhibits its cellular effects in polycythemia vera in the bone marrow. Ropeginterferon...

colorectal cancer

U.S. Multisociety Task Force on Colorectal Cancer  Releases Updated Screening Recommendations

The U.S. Multisociety Task Force on Colorectal Cancer—representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy—has updated its colorectal cancer screening recommendations, which were last published...

leukemia

Novel Drug Combination May Help Children With Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy

A clinical trial recently published by Kutny et al in JAMA Oncology found that the combination of all-trans retinoic acid and arsenic trioxide was highly effective in children with standard- and high-risk acute promyelocytic leukemia (APL). Nearly all patients in the trial survived for 2 years...

Study Examines Immunotherapy Outcomes in Patients With Solid Tumors Who Are Ineligible for Clinical Trials

Patients with solid tumors who are ineligible for clinical trials receive immune checkpoint inhibitors at greater rates than patients who are eligible, despite no survival benefit, according to a recent study by researchers at the Perelman School of Medicine at the University of Pennsylvania. The...

President Biden Nominates Robert M. Califf, MD, MACC, as FDA Commissioner

President Joseph Biden has nominated Robert M. Califf, MD, MACC, for the position of Commissioner of the U.S. Food and Drug Administration (FDA). Dr. Califf is an internationally recognized expert in clinical trial research, health disparities, health-care quality, and cardiovascular medicine....

Researchers Identify Key Link Between Stress and Cancer

Stress can have a significant negative effect on health, but our understanding of how stress impacts the development and progression of cancer is just beginning. A team from Roswell Park Comprehensive Cancer Center has identified an important mechanism by which chronic stress weakens immunity and...

covid-19

Study Examines COVID-19 Outcomes in Pediatric Patients With Cancer

Most children and adolescents with cancer have mild COVID-19 disease and make a full recovery, a new study by Haeusler et al in the European Journal of Cancer has found. But pediatric patients with cancer and underlying health conditions, severe infections, and low white blood cell counts were...

global cancer care

Living in Survival Mode

About 10 years ago, on a flight to Detroit, while returning from the San Antonio Breast Cancer Symposium, I had a conversation with Lori Pierce, MD, FASTRO, FASCO, radiation oncologist at the University of Michigan, who went on to become ASCO President for the 2020–2021 term. I recall inviting her...

David Morse Livingston, MD, Scientist and Esteemed Mentor, Dies at 80

David Morse Livingston, MD, formerly the Charles A. Dana Chair in Human Cancer Genetics at Dana-Farber and the Emil Frei III Distinguished Professor of Medicine at Harvard Medical School, died unexpectedly on October 17, 2021. He was Deputy Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) ...

Lung Cancer Research Foundation Names 2021 Recipients of Grant on Disparities in Lung Cancer

The Lung Cancer Research Foundation (LCRF) has announced the recipients of the 2021 LCRF Research Grant on Disparities in Lung Cancer, awarding $300,000 in research grants for projects focused on disparities in lung cancer. This funding mechanism will provide $150,000 over a period of 2 years...

Pamela Kunz, MD, Named 2021 Woman Oncologist of the Year

Women Leaders in Oncology has named Pamela Kunz, MD, the 2021 Woman Oncologist of the Year. Dr. Kunz is Associate Professor of Medicine (Medical Oncology), Director of the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and Yale Cancer Center, Chief of GI Medical Oncology, and Vice...

Mary Pasquinelli, DNP, APRN, FNP-BC, Receives 2021 National Leadership Award From the Prevent Cancer Foundation

Mary Pasquinelli, DNP, APRN, FNP-BC, was the recipient of this year’s James L. Mulshine, MD, National Leadership Award presented during the Prevent Cancer Foundation’s Quantitative Imaging Workshop held virtually earlier in November. Dr. Pasquinelli is a nurse practitioner in the Division of...

WHO Director-General Grants Posthumous Award to Henrietta Lacks

World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus, MD, honored the late Henrietta Lacks with a WHO Director-General’s award, recognizing her world-changing legacy. Ms. Lacks, a Black American woman, died of cervical cancer 70 years ago, on October 4, 1951. While she...

Susan G. Komen Announces $1.5 Million in Grants for Metastatic Breast Cancer Research

Susan G. Komen, the world’s leading breast cancer organization, recently announced the award of $1.5 million for three new research projects that examine unique areas focused on metastatic breast cancer. The grants are part of the Susan G. Komen Metastatic Breast Cancer Collaborative Research...

leukemia
lymphoma

Jennifer A. Woyach, MD, on CLL/SLL: Using Minimal Residual Disease Assessment in Clinical Practice

Jennifer A. Woyach, MD, of The Ohio State University Comprehensive Cancer Center, talks about whether modifications of treatment based on minimal residual disease is beneficial to patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

leukemia

Alice S. Mims, MD, on AML: Updates on Managing Newly Diagnosed Disease

Alice S. Mims, MD, of The Ohio State University Comprehensive Cancer Center, discusses the many positive changes over the past 5 years in treating patients with newly diagnosed acute myeloid leukemia in the upfront setting. She also details future directions, including further combining therapies...

prostate cancer

Howard M. Sandler, MD, on Prostate Cancer Highlights: An Expert Perspective

Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses whether hypofractionation can be safely employed in the post-prostatectomy setting and the role of short-term hormone therapy in the management of intermediate-risk prostate cancer with radiotherapy.

AACI Recognizes Robert A. Winn, MD, With Inaugural Cancer Health Equity Award

The Association of the American Cancer Institutes (AACI) Vice President/President-Elect Robert A. Winn, MD, Director of Virginia Commonwealth University Massey Cancer Center, recently received the AACI Cancer Health Equity Award. Dr. Winn is the inaugural recipient of the award, which was presented ...

Advertisement

Advertisement




Advertisement